Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. MSTR

Go back to Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
Merck & Co. (NYSE: MRK) Delayed: 115.46 +1.59 (1.40%)
Previous Close $113.87    52 Week High $65.46 
Open $113.97    52 Week Low $47.97 
Day High $115.63    P/E 78.54 
Day Low $113.00    EPS $1.47 
Volume 6,754,778